Oncology Institute (DFPH) Cash from Financing Activities (2020 - 2026)

Oncology Institute (DFPH) has 7 years of Cash from Financing Activities data on file, last reported at -$28000.0 in Q1 2026.

• Quarterly Cash from Financing Activities rose 99.41% year-over-year to -$28000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $16.3 million (up 323.05% YoY) and the FY2025 annual result came in at $11.6 million, up 430.96% from the prior year.
• Cash from Financing Activities fell to -$28000.0 in Q1 2026, from $3.7 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $105.4 million in Q3 2022 to a low of -$10.7 million in Q2 2022.
• A 5-year average of $5.5 million and a median of -$847000.0 in 2022 frame the typical range for Cash from Financing Activities.
• Annual changes were most pronounced in 2022 — Cash from Financing Activities soared 1317537.5% — and 2025, when it plunged 405.33%.
• Tracing DFPH's Cash from Financing Activities over 5 years: stood at -$847000.0 in 2022, then tumbled by 110.27% to -$1.8 million in 2023, then surged by 90.79% to -$164000.0 in 2024, then jumped by 2376.83% to $3.7 million in 2025, then plunged by 100.75% to -$28000.0 in 2026.
• The last three Cash from Financing Activities figures came in at -$28000.0 (Q1 2026), $3.7 million (Q4 2025), and $10.6 million (Q3 2025), per Business Quant data.